Bridgeway Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Bridgeway Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-91,144	Closed	-$643K	–	1382
2020 Q1	$643K	Hold	91,144	–	–	0.01%	677
2019 Q4	$643K	Hold	91,144	–	–	0.01%	870
2019 Q3	$1.09M	Hold	91,144	–	–	0.02%	700
2019 Q2	$1.1M	Sell	91,144 -30,256	-25%	-$334K	0.01%	705
2019 Q1	$1.53M	Buy	121,400 +35,800	+42%	+$316K	0.02%	619
2018 Q4	$576K	Hold	85,600	–	–	0.01%	952
2018 Q3	$881K	Buy	85,600 +35,000	+69%	+$301K	0.01%	935
2018 Q2	$340K	Buy	50,600 +11,600	+30%	+$89.1K	﹤0.01%	1228
2018 Q1	$335K	Hold	39,000	–	–	﹤0.01%	1179
2017 Q4	$811K	Hold	39,000	–	–	0.01%	925
2017 Q3	$689K	Buy	+39,000	New	+$540K	0.01%	986

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bridgeway Capital Management's PTGX Position: Q2 2020 in Review

Bridgeway Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2020, closing a stake of 91,144 shares — an estimated $643K sold.

Bridgeway Capital Management first reported a position in PTGX in Q3 2017 and held it in 11 quarters. The position peaked at $1.53M in Q1 2019. 85 funds tracked by Wall St. Rank hold PTGX as of Q2 2020.

Bridgeway Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2020 after selling out during the quarter.
Bridgeway Capital Management sold 91,144 Protagonist Therapeutics shares in Q2 2020, an estimated $643K.
Bridgeway Capital Management first reported a position in Protagonist Therapeutics in Q3 2017 and held it in 11 quarters.
Bridgeway Capital Management's Protagonist Therapeutics position peaked at $1.53M in Q1 2019.
85 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2020.

Based on Bridgeway Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.